Pharma major Lupin Ltd. announced that its subsidiary Lupin Pharmaceuticals Inc. had received final approval for its Levonorgestrel and Ethinyl Estradiol tablets, USP 0.15 mg/0.03 mg, from the US FDA to market a generic version of Teva Branded Pharmaceuticals Seasonale tablets - Levonorgestrel and Ethinyl Estradiol tablets, USP, 0.15 mg/0.03 mg.
Levonorgestrel and Ethinyl Estradiol tablets, USP, 0.15 mg/0.03 mg are the AB-rated generic equivalent of Teva's Seasonale tablets. Lupin's Levonorgestrel and Ethinyl Estradiol are a combined oral contraceptive indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception.
The company is marketing Levonorgestrel and Ethinyl Estradiol in 84 pink active tablets containing 0.15 mg of Levonorgestrel, a synthetic progestogen and 0.03 mg Ethinyl Estradiol, and 7 white inert tablets.
As per IMS MATJune 2012 sales data, Seasonale tablets had annual US sales of around $81.2 million.
At the BSE, Lupin closed Thursday's trading at Rs.574, up 2.01 percent from the previous close.
For comments and feedback: editorial@rttnews.com